Antisense Technology

Oligodeoxynucleotides To Purge Bone Marrow in CML

Published in Blood Weekly, July 31st, 1995

With additional fine tuning, targeted antisense oligodeoxynucleotides to bcr-abl have the potential to be used as ex vivo purging agents for use with autologous bone marrow transplantation in the treatment of chronic myeloid leukemia (CML).

CML is a neoplastic disorder of the hematopoietic stem cell in which the leukemic cells have a specific chromosomal defect termed the Philadelphia (Ph) chromosome. This chromosome is characterized by a translocation that results in the fusion of c-abl and the major bcr genes. The BCR-ABL tyrosine kinase has enhanced activity over wild-type c-ABL and is thought to play a central role in CML pathogenesis.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1995-07-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry